Literature DB >> 184134

Hypersensitivity to histamine and systemic anaphylaxis in mice with pharmacologic beta adrenergic blockade: protection by nucleotides.

Y Matsumura, E M Tan, J H Vaughan.   

Abstract

The effects of exogenous nucleotides on the histamine hypersensitivity of pharmacologically beta-blocked mice were investigated. Female HLA-SW (ICR) mice, 27-29 gm, were injected intraperitoneally with 20 to 100 mug of propranolol 45 min before intraperitoneal challenge with 1 mg histamine. These animals had a mortality which averaged approximately 80%. At various time intervals before histamine, doses of from 0.5 to 12 mumoles of nucleotides were administered intravenously. Noncyclic nucleotides, adenosine, adenosine 5'-monophosphate (AMP), and guanosine 5'-monophosphate (GMP) showed clear, dose-response protection against histamine death of propranolol-treated mice when they were given 45 to 90 min before histamine. Cyclic AMP showed significant protection only when it was given at a dose of 8 mumoles 45 to 90 min before histamine, and lower or higher doses gave equivocal or no protection. Cyclic GMP WAS Not protective at any dose tested. Propranolol treatment also produced enhanced sensitivity to passive systemic anaphylaxis. Mice were passively sensitized by intraperitoneal injection of mouse anti-egg albumin antibody 6 hr before intravenous challenge with 0.5 mg egg albumin. The mortality from anaphylaxis in the group treated with 20 mug propranolol 45 min before antigen challenge increased to 83%, while that of the group not given propranolol was only 10%. Nucleotides were given intravenously 45 min before antigen challenge. The nucleotides that protected mice from death due to histamine challenge also protected them from death due to systemic anaphylaxis. These protective nucleotides were the same nucleotides that had been reported previously to be protective against Bordetella pertussis-induced hypersensitivity to histamine and anaphylaxis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 184134     DOI: 10.1016/0091-6749(76)90119-6

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  8 in total

Review 1.  Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy?

Authors:  David M Lang
Journal:  Curr Allergy Asthma Rep       Date:  2008-03       Impact factor: 4.806

Review 2.  The risk and management of anaphylaxis in the setting of immunotherapy.

Authors:  Phil Lieberman
Journal:  Am J Rhinol Allergy       Date:  2012 Nov-Dec       Impact factor: 2.467

3.  Skin prick testing in patients using beta-blockers: a retrospective analysis.

Authors:  Irene N Fung; Harold L Kim
Journal:  Allergy Asthma Clin Immunol       Date:  2010-01-20       Impact factor: 3.406

Review 4.  Beta-blocker therapy and the risk of anaphylaxis.

Authors:  J H Toogood
Journal:  CMAJ       Date:  1987-05-01       Impact factor: 8.262

Review 5.  Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers.

Authors:  D M Lang
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

6.  Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions.

Authors:  Benjamin D McNeil; Priyanka Pundir; Sonya Meeker; Liang Han; Bradley J Undem; Marianna Kulka; Xinzhong Dong
Journal:  Nature       Date:  2014-12-17       Impact factor: 49.962

7.  Diamine oxidase knockout mice are not hypersensitive to orally or subcutaneously administered histamine.

Authors:  Matthias Karer; Marlene Rager-Resch; Teresa Haider; Karin Petroczi; Elisabeth Gludovacz; Nicole Borth; Bernd Jilma; Thomas Boehm
Journal:  Inflamm Res       Date:  2022-03-18       Impact factor: 4.575

Review 8.  Contraindications to immunotherapy: a global approach.

Authors:  C Pitsios; M Tsoumani; M B Bilò; G J Sturm; P Rodríguez Del Río; R Gawlik; F Ruëff; G Paraskevopoulos; E Valovirta; O Pfaar; M A Calderón; P Demoly
Journal:  Clin Transl Allergy       Date:  2019-09-11       Impact factor: 5.871

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.